» Articles » PMID: 39866838

At the Nucleus of Cancer: How the Nuclear Envelope Controls Tumor Progression

Overview
Journal MedComm (2020)
Date 2025 Jan 27
PMID 39866838
Authors
Affiliations
Soon will be listed here.
Abstract

Historically considered downstream effects of tumorigenesis-arising from changes in DNA content or chromatin organization-nuclear alterations have long been seen as mere prognostic markers within a genome-centric model of cancer. However, recent findings have placed the nuclear envelope (NE) at the forefront of tumor progression, highlighting its active role in mediating cellular responses to mechanical forces. Despite significant progress, the precise interplay between NE components and cancer progression remains under debate. In this review, we provide a comprehensive and up-to-date overview of how changes in NE composition affect nuclear mechanics and facilitate malignant transformation, grounded in the latest molecular and functional studies. We also review recent research that uses advanced technologies, including artificial intelligence, to predict malignancy risk and treatment outcomes by analyzing nuclear morphology. Finally, we discuss how progress in understanding nuclear mechanics has paved the way for mechanotherapy-a promising cancer treatment approach that exploits the mechanical differences between cancerous and healthy cells. Shifting the perspective on NE alterations from mere diagnostic markers to potential therapeutic targets, this review calls for further investigation into the evolving role of the NE in cancer, highlighting the potential for innovative strategies to transform conventional cancer therapies.

Citing Articles

At the nucleus of cancer: how the nuclear envelope controls tumor progression.

Paganelli F, Poli A, Truocchio S, Martelli A, Palumbo C, Lattanzi G MedComm (2020). 2025; 6(2):e70073.

PMID: 39866838 PMC: 11758262. DOI: 10.1002/mco2.70073.

References
1.
Wang J, Kondo T, Nakazawa T, Oishi N, Mochizuki K, Katoh R . Constitutional abnormality of nuclear membrane proteins in small cell lung carcinoma. Virchows Arch. 2019; 475(4):407-414. DOI: 10.1007/s00428-019-02597-7. View

2.
Stephens P, Tarpey P, Davies H, Van Loo P, Greenman C, Wedge D . The landscape of cancer genes and mutational processes in breast cancer. Nature. 2012; 486(7403):400-4. PMC: 3428862. DOI: 10.1038/nature11017. View

3.
Evangelisti C, Paganelli F, Giuntini G, Mattioli E, Cappellini A, Ramazzotti G . Lamin A and Prelamin A Counteract Migration of Osteosarcoma Cells. Cells. 2020; 9(3). PMC: 7140691. DOI: 10.3390/cells9030774. View

4.
Poli A, Pennacchio F, Ghisleni A, Di Gennaro M, Lecacheur M, Nastaly P . PIP4K2B is mechanoresponsive and controls heterochromatin-driven nuclear softening through UHRF1. Nat Commun. 2023; 14(1):1432. PMC: 10015053. DOI: 10.1038/s41467-023-37064-0. View

5.
Fricker M, Hollinshead M, White N, Vaux D . Interphase nuclei of many mammalian cell types contain deep, dynamic, tubular membrane-bound invaginations of the nuclear envelope. J Cell Biol. 1997; 136(3):531-44. PMC: 2134289. DOI: 10.1083/jcb.136.3.531. View